Overview

Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This study evaluates the combination of two well-tolerated therapies, osimertinib and Stereotactic Ablative Radiation (SABR).
Phase:
Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborator:
AstraZeneca
Treatments:
Osimertinib